1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2021 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -7.64m | 138.46% |
| EBITDA | -7.62m | 156.30% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €8.56m |
Number of shares | 69.01m |
52-week high/low | €0.82 - €0.11 |
| Dividends | No |
Beta | 0.44 |
P/E ratio | -1.23 |
PEG ratio | 0.03 |
P/B ratio | 2.51 |
P/S ratio | 0.00 |
Company profile
ISR Immune System Regulation Holding AB (publ) erforscht und entwickelt in Schweden Arzneimittel für die Behandlung von Virusinfektionen. Die Produktpipeline des Unternehmens umfasst den Impfstoff Covid-19, HBV, HIV und Onkologie. Der Hauptsitz des Unternehmens befindet sich in Stockholm, Schweden.
| Name | ISR IMMUNE SYS.REGUL.HLDG |
| CEO | Ola S. Winqvist |
| Headquarters | Stockholm,
Sweden |
| Website | |
| IPO | 24/03/2017 |
| Employees | 5 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Sto | ISR.ST |
